石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02005 石四药集团

交易中 05-06 11:34:35

2.960

+0.010

+0.34%

最高2.980	最低2.940	成交量124.60万
今开2.960	昨收2.950	日振幅1.36%
总市值87.35亿	流通市值87.35亿	总股本29.51亿
成交额368.63万	换手率0.04%	流通股本29.51亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"石四药集团","latestPrice":2.96,"timestamp":1746502198663,"preClose":2.95,"halted":0,"volume":1246000,"delay":0,"floatShares":2951000000,"shares":2951000000,"eps":0.358192,"marketStatus":"交易中","change":0.01,"latestTime":"05-06 11:34:35","open":2.96,"high":2.98,"low":2.94,"amount":3686260,"amplitude":0.013559,"askPrice":2.97,"askSize":304000,"bidPrice":2.95,"bidSize":234000,"shortable":3,"etf":0,"ttmEps":0.358099,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1746504000000},"marketStatusCode":2,"adr":0,"listingDate":1135008000000,"exchange":"SEHK","adjPreClose":2.95,"dividendRate":0.060811,"openAndCloseTimeList":[[1746495000000,1746504000000],[1746507600000,1746518400000]],"volumeRatio":0.864959,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005","defaultTab":"news","newsList":[{"id":"2531079083","title":"石四药集团(02005)4月30日注销280万股已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2531079083","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531079083?lang=zh_cn&edition=full","pubTime":"2025-04-30 17:37","pubTimestamp":1746005831,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)公布，2025年4月30日注销280万股已回购股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02005","LU2460026573.USD"],"gpt_icon":0},{"id":"2531085178","title":"石四药集团04月30日主力净流入134.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2531085178","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531085178?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:15","pubTimestamp":1746000936,"startTime":"0","endTime":"0","summary":"04月30日，石四药集团股价收平报2.95元，成交金额1170.9万元，换手率0.13%，振幅1.36%，量比0.88。石四药集团今日主力资金净流入134.1万元，上一交易日主力净流出164.1万元。该股近5个交易日下跌2.96%，主力资金累计净流出314.2万元；近20日主力资金累计净流入2358.0万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170855a46d74c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170855a46d74c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02005","LU2460026573.USD"],"gpt_icon":0},{"id":"2531542204","title":"石四药集团(02005)：氯诺昔康已获国家药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2531542204","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531542204?lang=zh_cn&edition=full","pubTime":"2025-04-29 17:54","pubTimestamp":1745920441,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，集团的氯诺昔康已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。氯诺昔康主要用于治疗急性中度手术后疼痛以及与急性腰、坐骨神经相关的疼痛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02005","LU2460026573.USD"],"gpt_icon":0},{"id":"2530416384","title":"石四药集团：别嘌醇已获国家药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2530416384","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530416384?lang=zh_cn&edition=full","pubTime":"2025-04-28 12:03","pubTimestamp":1745813035,"startTime":"0","endTime":"0","summary":"格隆汇4月28日丨石四药集团(02005.HK)公告，集团的别嘌醇已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。别嘌醇主要用于治疗痛风和高尿酸。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042812043494e55786&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042812043494e55786&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02005","BK1191","LU2460026573.USD"],"gpt_icon":0},{"id":"2530647903","title":"石四药集团04月25日主力净流出219万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2530647903","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530647903?lang=zh_cn&edition=full","pubTime":"2025-04-25 16:15","pubTimestamp":1745568940,"startTime":"0","endTime":"0","summary":"04月25日, 石四药集团股价跌0.33%，报收3.01元，成交金额1383万元，换手率0.16%，振幅2.32%，量比0.81。石四药集团今日主力资金净流出219万元，上一交易日主力净流出0万元。该股近5个交易日上涨2.03%，主力资金累计净流入118万元；近20日主力资金累计净流入2321万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425170131a6c7cd1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425170131a6c7cd1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02005","LU2460026573.USD"],"gpt_icon":0},{"id":"2529023143","title":"石四药集团：取得达格列净二甲双胍缓释片(Ⅰ)(达格列净10mg和盐酸二甲双胍1000mg)及精氨酸布洛芬颗粒(0.4g及0.2g)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2529023143","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529023143?lang=zh_cn&edition=full","pubTime":"2025-04-22 20:36","pubTimestamp":1745325409,"startTime":"0","endTime":"0","summary":"格隆汇4月22日丨石四药集团公告，集团已取得中国国家药品监督管理局有关达格列净二甲双胍缓释片(Ⅰ)及精氨酸布洛芬颗粒的药品生产注册批件，均属于化学药品第4类，视同通过一致性评价。达格列净二甲双胍缓释片(Ⅰ)主要用于2型糖尿病成人患者改善血糖控制，而精氨酸布洛芬颗粒主要用于下列症状：牙痛、痛经、因创伤引起的疼痛、关节和韧带痛、背痛、头痛、神经痛以及流感引起的发热。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042220364994de207a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042220364994de207a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02005","BK1191","LU2460026573.USD"],"gpt_icon":0},{"id":"2527247719","title":"石四药集团获主席兼执行董事曲继广增持58万股 每股作价约3.03港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527247719","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527247719?lang=zh_cn&edition=full","pubTime":"2025-04-16 07:56","pubTimestamp":1744761360,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，4月15日，主席兼执行董事曲继广增持石四药集团（02005）58万股，每股作价3.0321元，总金额约为175.86万港元。增持后最新持股数目为11.64亿股，最新持股比例为39.41%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-16/doc-inetifia7128479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","LU2460026573.USD","02005"],"gpt_icon":0},{"id":"2527147443","title":"石四药集团(02005.HK)获执行董事兼主席兼行政总裁曲继广增持58万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2527147443","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527147443?lang=zh_cn&edition=full","pubTime":"2025-04-16 06:51","pubTimestamp":1744757472,"startTime":"0","endTime":"0","summary":"格隆汇4月16日丨根据联交所最新权益披露资料显示，2025年4月15日，石四药集团(02005.HK)获执行董事兼主席兼行政总裁曲继广在场内以每股均3.0321港元增持58万股，涉资约175.86万港元。增持后，曲继广最新持股数目为1,164,306,000股，持股比例由39.39%上升至39.41%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/16065149565894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","02005","LU2460026573.USD"],"gpt_icon":0},{"id":"2527166594","title":"主席兼执行董事曲继广增持石四药集团(02005)58万股 每股作价约3.03港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527166594","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527166594?lang=zh_cn&edition=full","pubTime":"2025-04-15 20:45","pubTimestamp":1744721117,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，4月15日，主席兼执行董事曲继广增持石四药集团(02005)58万股，每股作价3.0321元，总金额约为175.86万港元。增持后最新持股数目为11.64亿股，最新持股比例为39.41%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191","LU2460026573.USD"],"gpt_icon":0},{"id":"2527366134","title":"石四药集团04月14日主力净流入405万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2527366134","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527366134?lang=zh_cn&edition=full","pubTime":"2025-04-14 16:17","pubTimestamp":1744618640,"startTime":"0","endTime":"0","summary":"04月14日, 石四药集团股价涨0.66%，报收3.06元，成交金额2593万元，换手率0.29%，振幅1.32%，量比0.74。石四药集团今日主力资金净流入405万元，上一交易日主力净流出197万元。该股近5个交易日上涨3.03%，主力资金累计净流入102万元；近20日主力资金累计净流入2401万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414171619a4584d5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414171619a4584d5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU2460026573.USD","02005"],"gpt_icon":0},{"id":"2518266202","title":"【石四药集团(02005.HK)获国药监局有关安瓿包装的碳酸氢钠注射液(10ml: 0.84g)的药品生产注册批件】石四药集团(02005.HK)发布公告，该集团已取得中国国家药品监督管理局有关安瓿包装的碳酸氢钠注射液(10ml: 0.84g)的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518266202","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518266202?lang=zh_cn&edition=full","pubTime":"2025-03-10 12:36","pubTimestamp":1741581380,"startTime":"0","endTime":"0","summary":"石四药集团(02005.HK)发布公告，该集团已取得中国国家药品监督管理局有关安瓿包装的碳酸氢钠注射液(10ml: 0.84g)的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/10123648620305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","LU2460026573.USD","02005"],"gpt_icon":0},{"id":"2518653202","title":"石四药集团(02005.HK)：碳酸氢钠注射液(10ml:0.84g)获药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2518653202","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518653202?lang=zh_cn&edition=full","pubTime":"2025-03-10 12:06","pubTimestamp":1741579577,"startTime":"0","endTime":"0","summary":"格隆汇3月10日丨石四药集团(02005.HK)公告，集团已取得中国国家药品监督管理局有关安瓿包装的碳酸氢钠注射液(10ml:0.84g)的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。安瓿包装的碳酸氢钠注射液主要用于治疗代谢性酸中毒、硷化尿液及静脉滴注对某些药物的中毒。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/10120648620058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","02005","LU2460026573.USD"],"gpt_icon":0},{"id":"2517571995","title":"石四药集团03月05日获主力加仓281万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517571995","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517571995?lang=zh_cn&edition=full","pubTime":"2025-03-05 16:16","pubTimestamp":1741162563,"startTime":"0","endTime":"0","summary":"03月05日, 石四药集团股价涨0.32%，报收3.18元，成交金额1723万元，换手率0.18%，振幅2.52%，量比0.94。石四药集团今日主力资金净流入281万元，上一交易日主力净流入50万元。该股近5个交易日下跌3.35%，主力资金累计净流出33万元；近20日主力资金累计净流入773万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305170127a26059ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305170127a26059ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU2460026573.USD","02005"],"gpt_icon":0},{"id":"2517395954","title":"石四药集团盐酸尼卡地平获批上市制剂原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2517395954","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517395954?lang=zh_cn&edition=full","pubTime":"2025-03-05 12:35","pubTimestamp":1741149308,"startTime":"0","endTime":"0","summary":"3月5日，石四药集团（02005）发布公告，近日公司获得中国国家药品监督管理局批准，盐酸尼卡地平已登记为上市制剂使用的原料药。盐酸尼卡地平主要用于治疗高血压，此次批准标志着公司在产品开发方面取得了重要进展。公告的目的是为了让股东及潜在投资者了解公司的最新业务发展情况。此次批准将有助于公司进一步拓展市场，提高产品竞争力，促进公司未来的业绩增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503053337071017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2460026573.USD","BK1191","02005"],"gpt_icon":0},{"id":"2517959917","title":"石四药集团(02005)：盐酸尼卡地平已获国家药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2517959917","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517959917?lang=zh_cn&edition=full","pubTime":"2025-03-05 12:05","pubTimestamp":1741147549,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，集团的盐酸尼卡地平已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。盐酸尼卡地平主要用于治疗高血压。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)：盐酸尼卡地平已获国家药监局批准登记成为在上市制剂使用的原料药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"gpt_icon":0},{"id":"2514080351","title":"瑞银减持石四药集团(02005)37.2万股 每股作价约3.24港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514080351","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514080351?lang=zh_cn&edition=full","pubTime":"2025-02-27 19:17","pubTimestamp":1740655072,"startTime":"0","endTime":"0","summary":"2月21日，瑞银减持石四药集团(02005)37.2万股，每股作价3.2439港元","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20250227/20250227191818_14369.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250227/20250227191818_14369.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","LU2460026573.USD","02005"],"gpt_icon":0},{"id":"2514897192","title":"石四药集团获瑞银增持9.8万股 每股作价约3.33港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514897192","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514897192?lang=zh_cn&edition=full","pubTime":"2025-02-27 08:09","pubTimestamp":1740614940,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，2月20日，瑞银增持石四药集团（02005）19.8万股，每股作价3.3349港元，总金额约为66.03万港元。增持后最新持股数目约为2.66亿股，最新持股比例为9%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-02-27/doc-inemwpwr8149138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","LU2460026573.USD","02005"],"gpt_icon":0},{"id":"2514389232","title":"石四药集团(02005.HK)获UBS Group AG增持19.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2514389232","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514389232?lang=zh_cn&edition=full","pubTime":"2025-02-27 07:35","pubTimestamp":1740612947,"startTime":"0","endTime":"0","summary":"格隆汇2月27日丨根据联交所最新权益披露资料显示，2025年2月20日，石四药集团(02005.HK)获UBS Group AG在场内以每股均价3.3349港元增持19.8万股，涉资约66.03万港元。增持后，UBS Group AG最新持股数目为265,867,466股，持股比例由8.99%上升至9.00%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/27073548414564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4588","UBS","LU2460026573.USD","02005","AG","IE0034235071.USD","BK4118","BK4534","BK4585","BK1191","LU1829250122.USD","BK4210"],"gpt_icon":0},{"id":"2514130836","title":"瑞银增持石四药集团(02005)19.8万股 每股作价约3.33港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514130836","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514130836?lang=zh_cn&edition=full","pubTime":"2025-02-26 18:57","pubTimestamp":1740567443,"startTime":"0","endTime":"0","summary":"2月20日，瑞银增持石四药集团(02005)19.8万股，每股作价3.3349港元","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20250226/20250226185753_93102.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250226/20250226185753_93102.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02005","LU2460026573.USD","BK1191"],"gpt_icon":0},{"id":"2514230039","title":"石四药集团获氨甲环酸片及阿昔莫司胶囊生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2514230039","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514230039?lang=zh_cn&edition=full","pubTime":"2025-02-25 12:22","pubTimestamp":1740457355,"startTime":"0","endTime":"0","summary":"2月25日，石四药集团（02005）发布公告，近日公司取得了中国国家药品监督管理局关于氨甲环酸片（0.5g）和阿昔莫司胶囊（0.25g）的药品生产注册批件。氨甲环酸片作为化学药品第4类，主要用于急性或慢性、局限性或全身性原发性纤维蛋白溶解亢进所致的各种出血，这使得公司成为国内第三家获批的企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502253328825776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02005","BK1191","LU2460026573.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.1424},{"period":"3month","weight":-0.0665},{"period":"6month","weight":-0.2237},{"period":"1year","weight":-0.3584},{"period":"ytd","weight":-0.1737}],"compareEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":-0.0301},{"period":"3month","weight":0.1127},{"period":"6month","weight":0.0974},{"period":"1year","weight":0.236},{"period":"ytd","weight":0.1219}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石四药集团有限公司,前称为利君国际医药（控股）有限公司，是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药，包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.006453},{"month":2,"riseRate":0.55,"avgChangeRate":0.026012},{"month":3,"riseRate":0.7,"avgChangeRate":0.087482},{"month":4,"riseRate":0.5,"avgChangeRate":0.035816},{"month":5,"riseRate":0.4,"avgChangeRate":0.008529},{"month":6,"riseRate":0.526316,"avgChangeRate":0.074239},{"month":7,"riseRate":0.315789,"avgChangeRate":-0.035588},{"month":8,"riseRate":0.368421,"avgChangeRate":-0.014197},{"month":9,"riseRate":0.263158,"avgChangeRate":-0.051674},{"month":10,"riseRate":0.421053,"avgChangeRate":-0.005249},{"month":11,"riseRate":0.684211,"avgChangeRate":0.09121},{"month":12,"riseRate":0.526316,"avgChangeRate":-0.005499}],"exchange":"SEHK","name":"石四药集团","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石四药集团,02005,石四药集团股票,石四药集团股票老虎,石四药集团股票老虎国际,石四药集团行情,石四药集团股票行情,石四药集团股价,石四药集团股市,石四药集团股票价格,石四药集团股票交易,石四药集团股票购买,石四药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}